Supporting Information

Bioaccumulation, Biotransformation, and Synergistic Effects of Binary Fungicide

Mixtures in Hyalella azteca and Gammarus pulex: How Different/Similar Are the Two

Species?

Qiuguo Fu,^{†, #} Andrea Rösch ,^{†, ‡, #} Davide Fedrizzi, ^{†,§} Caroline Vignet, [†] and Juliane

Hollender^{†, ‡, *}

[†] Eawag, Swiss Federal Institute of Aquatic Science and Technology, 8600 Dübendorf,

Switzerland

[‡] Institute of Biogeochemistry and Pollutant Dynamics, ETH Zürich, 8092 Zürich,

Switzerland

§ Department of Plant and Environmental Sciences, University of Copenhagen, 1871

Frederiksberg C, Denmark

[#] Qiuguo Fu and Andrea Rösch contributed equally to this work.

Corresponding author: juliane.hollender@eawag.ch

Total pages: 70

Number of Supplementary Tables: 18

Number of Supplementary Figures: 7

S1

Contents

SI. A	Chemicals and Solutions	3
SI. B	Hyalella azteca and Gammarus pulex Cultivation	4
SI. C	Sampling during the H. azteca Kinetic Experiments	4
SI. D	Quality Control	4
SI. E Compo	Biotransformation Product Identification in <i>H. azteca</i> by Suspect and Nontarget Screening ound Discoverer	_
SI. F	Modeling Bioaccumulation and Biotransformation Kinetics	7
SI. G	Lethal Concentrations of Azoxystrobin (LC50s) in the Presence and	11
SI. H for <i>H</i> .	Exposure Medium Concentrations, Internal Concentrations and Bioaccumulation Factors (Bazteca	
SI. I	Determination of IC _{50, PRZ, AZ} s in <i>H. azteca</i>	18
SI. J	Dose-Response Fitting of IC _{50, PRZ, AZ} s in <i>H. azteca</i>	19
SI. K exposu	Distance moved (cm) of the Video-Tracking of <i>G. pulex</i> and <i>H. azteca</i> during 18 h prochare	
SI. L Biotraı	Comparison of different <i>H. azteca</i> Sample Wet Weights for Detection and Quantificationsformation Products	
SI. M	Identified Biotransformation Products for Azoxystrobin and Prochloraz in H. azteca	22
Refere	nces	70

SI. A Chemicals and Solutions

Table S1: Fungicides. All standard solutions were prepared in methanol.

Substance	CAS number	Supplier	Quality	
Azoxystrobin	131860-33-8	Dr. Ehrenstorfer	99.5%	
Azoxystrobin acid	1185255-09-7	HPC Standards GmbH	99%	
Azoxystrobin-d4	1346606-39-0	Sigma-Aldrich	98%	
Prochloraz	67747-09-5	Dr. Ehrenstorfer	98.5%	
Prochloraz-d7		Dr. Ehrenstorfer	97%	

Table S2: Other chemicals and solvents.

Substance	CAS number	Supplier	Quality
Acetic acid	64-19-7	Merck	100%
Acetonitrile	75-05-8	Acros Organics	HPLC-grade
Ammonium acetate	631-61-8	Sigma-Aldrich	> 98%
Calcium chloride	10035-04-8	Sigma-Aldrich	> 99%
Ethanol	64-17-5	Merck	Analytical grade
Formic acid	64-18-6	Merck	98-100%
Magnesium sulfate	10034-99-8	Sigma-Aldrich	> 99%
Isopropanol	67-63-0	Fisher Chemicals	> 99%
Methanol	67-56-1	Fisher Chemicals	LC-MS grade
Potassium chloride	7447-40-7	Sigma-Aldrich	> 99%
Sodium acetate trihydrate	6131-90-4	Fluka	> 99.5%
Sodium hydrogen carbonate	144-55-8	Merck	> 99%
Sodium bromide	7647-15-6	Sigma-Aldrich	> 99%

SI. B Hyalella azteca and Gammarus pulex Cultivation

Hyalella azteca were kept in 1.5 L-glass beakers filled with previously aerated Borgmann water and were fed three times a week with approximately 30 mg ground fish food flasks. Each beaker contained approximately 100 organisms and a piece of cotton gauze as substrate to hold on to and hide. All beakers were placed in a water bath (23±1 °C) with a 16h light/8h dark cycle. Borgmann water was changed weekly and juvenile *H. azteca* were separated from the adults and kept in separated beakers.

Borgmann water (BW) composition¹: $0.03 \text{ g L}^{-1} \text{ MgSO}_4$, $0.084 \text{ g L}^{-1} \text{ NaHCO}_3$, $0.0037 \text{ g L}^{-1} \text{ KCl}$, $0.11 \text{ g L}^{-1} \text{ CaCl}_2$, and $0.001 \text{ g L}^{-1} \text{ NaBr}$.

Gammarus pulex were acclimatized in an aquarium with aerated artificial pond water (APW) for 3-5 days at 11 \pm 2 °C and 12 h/12 h light/dark conditions. G. pulex were fed with horse chestnut leaves inoculated with Cladosporium herbarum. Detailed information on the preparation of APW and the inoculation of leaves are found elsewhere.²

Artificial pond water (APW) composition³: $0.12 \text{ g L}^{-1} \text{ MgSO}_4 \cdot 7 \text{ H}_2\text{O}$, $0.065 \text{ g L}^{-1} \text{ NaHCO}_3$, $0.0058 \text{ g L}^{-1} \text{ KCl}$, and $0.29 \text{ g L}^{-1} \text{ CaCl}_2 \cdot 2\text{H}_2\text{O}$.

SI. C Sampling during the *H. azteca* Kinetic Experiments

Table S3: Sampled time-points during the azoxystrobin and prochloraz kinetic experiments.

Uptake (U) / Depuration (D)	Time [h]	Time [d]
U	0.5	0.02
U	1.5	0.06
U	2.5	0.10
U	5.5	0.23
U	9.5	0.40
U	17.5	0.73
U	24	1.00
D	24	1.00
D	25	1.04
D	26	1.08
D	28	1.17
D	31	1.29
D	35	1.46
D	42	1.75
D	50	2.08
D	65	2.71
D	95	3.96
D	119	4.96
D	144	6.00

SI. D Quality Control

Internal standard calibration was used for quantification using Trace Finder software 3.1, 3.3 and 4.1 (Thermo Scientific). In total, 16 calibration points were prepared in a range of 0.5-3000 ng L⁻¹ and the calibration curves were obtained by linear least square regression using a weighing factor of 1/x. All BTPs were quantified based

on the calibration curve of the corresponding parent compound except for azoxystrobin acid (AZ_M390b), for which a reference standard was available. Reference standards for two prochloraz BTPs (PRZ_M282 and PRZ_M325) were obtained after finishing the experiment and were only used for confirming the proposed structures.

Limits of Quantification (LOQ) and matrix factors were calculated according to our previous publications.²

Table S4: Calculated matrix factors for H. azteca extracts and limits of quantification (LOQs) for azoxystrobin and prochloraz in H. azteca extracts and in the exposure medium. Duplicate samples (prespike 1 and 2) were spiked before H. azteca extraction with 25 μ g L^{-1} (i.e., 5 ng absolute in 200 μ L measured extract) and 50 μ g L^{-1} (i.e., 10 ng absolute in 200 μ L measured extract) of azoxystrobin and prochloraz, respectively.

Compound		1	Matrix factors			LOQ* [nmol kg _{ww} -1]	LOQ** [ng L ⁻¹]
	Prespike 1 5 ng	Prespike 2 5 ng	Prespike 1 10 ng	Prespike 2 10 ng	Average	•	
Azoxystrobin	0.4	0.4	0.4	0.4	0.4	2.4	0.5
Prochloraz	0.6	0.6	0.6	0.6	0.6	1.7	0.5

^{*:} LOQ for H. azteca extract samples

Table S5: Relative recoveries for the whole sample preparation and analytical procedure. Duplicate samples (prespike 1 and 2) spiked before H. azteca extraction with 25 μ g L^{-1} (i.e., 5 ng absolute in 200 μ L measured extract) and 50 μ g L^{-1} (i.e., 10 ng absolute in 200 μ L measured extract) of the parent compounds, respectively, were used to determine the recovery of the whole procedure of sample preparation and chemical analysis.

Compound	Relative recovery [%]					
	Prespike 1	Prespike 2	Prespike 1	Prespike 2		
	5 ng	5 ng	10 ng	10 ng		
Azoxystrobin	101	101	104	98		
Prochloraz	115	118	107	99		

SI. E Biotransformation Product Identification in *H. azteca* by Suspect and Nontarget Screening using Compound Discoverer

Compound Discoverer small molecule identification software version 2.0 (Thermo Scientific) was used for suspect and nontarget screening by comparing treatment and control samples. As control samples "exposure medium controls", "chemical controls" (chemical positive, cotton gauze and organism negative), "organism controls" (chemical negative, organism and food positive) and "standard controls" (calibration standard) were used. "Standard controls" and "chemical controls" were additionally selected as control samples compared to the screening conducted with SIEVE software (Thermo Scientific) in our previous publications. ^{2,4} "Standard controls" account for impurities of the reference standards, and "chemical controls" provide in addition to the "exposure medium controls" evidence that BTPs are actually formed by the organisms and not due to *e.g.*, abiotic processes in the medium. Due to a high volume to organism ratio (500 mL exposure medium containing

^{**:} LOQ for medium samples

50 organisms) and since no additional enrichment of the exposure medium besides online-SPE was conducted, no BTPs formed by the organisms can be detected in the medium. Thus, the detection of BTPs in the exposure medium would point towards additional formation processes.

For suspect screening, the generated frame list was compared to the mass list of predicted BTPs. BTPs were predicted based on (i) *in silico* pathway prediction (Eawag-PPS, http://eawag-bbd.ethz.ch/predict/, Eawag-PPS predicts microbial degradation of chemicals based on biotransformation rules), (ii) *in silico* manual prediction of BTPs considering most common enzymatic biotransformation reactions, and (iii) identified BTPs of azoxystrobin and prochloraz reported in any organism in scientific literature. The mass lists for azoxystrobin and prochloraz contained 1325 and 490 predicted BTPs masses, respectively.

Framing describes the process of building regions in the m/z versus retention time plane, whereby all peaks above a given threshold are collected.

For nontarget screening, the generated frame list was filtered with (i) an integrated intensity threshold of 0.1% of the parent compound and (ii) an integrated intensity ratio between treatment and control samples of 10 (with the exception of the ratio "treatment / organisms control", which was adjusted individually, see below).

The workflow was validated with known low concentrated BTPs detected in previous work^{2,4} that were also detected in *H. azteca*. With the selected nontarget criteria the filtered frame list should still contain these low concentrated BTPs. The node "Fill Gaps", included in the applied workflow, fills in areas for missing peaks or for peaks with intensities below the chosen threshold. This is done to avoid dividing by zero to be still able to form ratios with control samples, where no peak was detected. For some of these low concentrated BTPs the ratio "treatment / organisms control" was considerably smaller than 10 due to "Fill Gaps". Therefore, the ratio "treatment / organisms control" was adopted to the observed conditions and reduced to 4 (AZ) and 3.8 (PRZ), respectively.

For both screening approaches, potential BTPs had to show increasing/decreasing intensities during the uptake/depuration phase. Moreover, Compound Discoverer allows to screen for specific isotopic patterns. Therefore, the presence of the chlorophenyl moiety (chlorine isotopic pattern) in potential BTPs that after biotransformation still contain the chlorophenyl moiety, facilitated BTP screening for prochloraz.

Table S6: Settings used for suspect and nontarget screening with Compound Discoverer (Thermo Scientific, version 2.0).

Retention time window	5-20 min
m/z window	100-1000
Minimal number of scans per peak	3
Maximum peak width	1 min
m/z tolerance	5 ppm
Peak intensity threshold	10^6

SI. F Modeling Bioaccumulation and Biotransformation Kinetics

For comparison with the simultaneous fitting approach, we further applied a stepwise fitting approach to determine the uptake and elimination rate of the parent compound by fitting the simplest compartment model (see SI. F) with only two parameters (k_u and k_e , total or parent) to the internal concentration of the parent compound.

$$\frac{dC_{in, p}(t)}{dt} = C_{water}(t) \cdot k_u - C_{in, p}(t) \cdot k_e$$
 equation S1

where $C_{in, p}(t)$ [nmol kg_{ww}⁻¹] is whole body internal concentration of azoxystrobin, $C_{water}(t)$ [nmol L⁻¹] is the time course of azoxystrobin in the exposure medium and k_u [L kg_{ww}⁻¹ d⁻¹] and k_e [d⁻¹] are the uptake and elimination rate constant, respectively. In this case k_e covers direct elimination of the parent compound as well as further elimination due to biotransformation.

In general, the simultaneously fitting approach of all rate constants and the stepwise fitting approach showed the same result (Figure S2 and S3) but for H. $azteca\ k_{m,\ lst,\ total}$ seemed to contribute more to the total elimination of the parent compound compared to G. pulex (see Figure 2 in the corresponding publication). Although especially for G. pulex, elimination of azoxystrobin was overpredicted by either of the models, elimination of azoxystrobin was faster in G. pulex compared to H. azteca and consequently the smaller $k_{m,\ lst,\ total}$ of G. pulex compared to those of H. azteca contributed less to the total elimination. Reason for the discrepancy of actual and simulated elimination could be a longer retention of azoxystrobin in any biomass component of aquatic organisms such as lipids, which is not covered by the applied simple one-compartment model assuming well-mixed organisms. However, elimination of azoxystrobin was simulated much better in H. azteca, although both species do not significantly deviate in their total lipid content (1.3-1.8% of wet weight), findicating that the change to a more complex model such as a two-compartment model does not necessarily improve the match between experimental data and model and might be more important for more lipophilic compounds and more lipid rich organisms.




Figure S1: Uptake and depuration kinetic for azoxystrobin in *G. pulex* (green) and *H. azteca* (blue) modeled with the simplest compartment model (see equation S1). Shown are the measured (dots) and modeled (lines) time courses for azoxystrobin in *G. pulex* and *H. azteca*. The dashed vertical line indicates the change from uptake (1 d) to depuration (5 d).

Table S7: Kinetic rate constants for azoxystrobin in the two species G. pulex and H. azteca (lower and upper 95% confidence internals are given in brackets) and kinetic bioaccumulation factors (BAF $_k$ s). The simplest compartment model (see equation S1) was used for fitting the kinetic rate constants. Results are rounded to three significant digits. Two replicate internal concentrations were used per time point.

	$egin{aligned} \mathbf{k_u} \\ [\mathbf{L} \ \mathbf{kg_{ww}}^{-1} \ \mathbf{d^{-1}}] \end{aligned}$	k _e [d ⁻¹]
<u>Azoxystrobin</u>		
G. pulex BAF _k AZ: 4.95 [L kg _{ww} ⁻¹]	42.2 [33.6; 55.7]	8.52 [6.81; 11.4]
H. azteca BAF _k AZ: 5.22 [L kg _{ww} ⁻¹]	14.7 [9.65; 20.3]	2.82 [1.68; 4.07]




Figure S2: Measured (dots) and modeled (lines) time series of internal concentrations of azoxystrobin, the sum of 1st BTPs and the sum of 2nd BTPs in *H. azteca* in the uptake (1 d) and depuration phase (5 d) shown in separate panels. All parameters were fitted simultaneously.




Figure S3: Measured (dots) and modeled (lines) time series of internal concentrations of azoxystrobin, the sum of 1st BTPs and the sum of 2nd BTPs in *H. azteca* in the uptake (1 d) and depuration phase (5 d) shown in separate panels. The uptake rate k_u [L kg_{ww}⁻¹ d⁻¹] was determined in a first step by only fitting the azoxystrobin parent compound kinetic with two parameters (k_u and k_e , see equation S1) and in a second step fixing k_u (14.7 L kg_{ww}⁻¹ d⁻¹, see Table S7) and simultaneously fitting k_e and the kinetic rate constants of the sum of 1st BTPs and the sum of 2nd BTPs, respectively.

Table S8: Comparison of kinetic rate constants of azoxystrobin, the sum of 1st BTPs and the sum of 2nd BTPs in *H. azteca*. Kinetic rate constants were either determined by simultaneously fitting of all kinetic rate constants or with a stepwise approach, by first only fitting the azoxystrobin parent compound kinetic with two parameters (k_u and k_e , see equation S1) and in a second step fixing k_u (14.7 L kg_{ww}⁻¹ d⁻¹, see Table S7) and simultaneously fitting k_e and the kinetic rate constants of the sum of 1st BTPs and the sum of 2nd BTPs, respectively.

fixed k_u (14.7 L $kg_{ww}^{-1} d^{-1}$, see Table S7)

simultaneously fitting of all kinetic

	rate constants	and simultaneously fitting of all remaining kinetic rate constants
k _e [d ⁻¹]:	0.131 [0.0001; 0.804]	0.001 [0.001; 1.77]
$k_u [L kg_{ww}^{-1} d^{-1}]$:	10.6 [9.40; 12.2]	-
$\mathbf{k}_{\mathrm{m, 1st, total}} [\mathbf{d}^{-1}]$:	1.75 [1.46; 1.48]; [1.57; 2.14]	2.74 [2.40; 3.05]
$\mathbf{k}_{\mathbf{m}, 2\mathbf{nd} \mathbf{total}} [\mathbf{d}^{-1}]$:	8.62 [7.60; 11.0]	6.42 [4.94; 8.14]
$\mathbf{k}_{\mathrm{e, 1st, total}} [\mathbf{d}^{-1}]$:	0.0001 [0.0001; 4.92]	7.97 [5.90; 9.78]
k _{em, 2nd, total} [d ⁻¹]:	1.85 [1.50; 2.52]	1.14 [0.69; 1.73]
total elimination azoxystrobin [$\mathbf{d}^{\text{-1}}$] ($\mathbf{k}_e + \mathbf{k}_{m, \text{ 1st, total}}$):	1.88	2.74
fraction $k_{m, 1st, total}$ on total elimination [%]:	93.0	100
$BAF_k AZ [L kg_{ww}^{-1}]$:	5.63	5.37

Table S9: Internal concentration (nmol kg_{ww}^{-1}) of azoxystrobin, prochloraz, and their BTPs in the two species during the toxicokinetic experiment.

			G. pulex		,	H. azteca			G. pulex		Н	I. azteca	
	Time [h]	AZ	AZ_ 1 st BTPs	AZ_2 nd BTPs	AZ	AZ_ 1 st BTPs	AZ_ 2 nd BTPs	PRZ	PRZ _1st BTPs	PRZ 2 nd BTPs	PRZ	PRZ _1st BTPs	PRZ 2 nd BTPs
	t0.5_1	154	3	0	110	0	0	1693	7	44	3850	6	65
	t_0.5_2	151	4	0	108	0	0	1433	2	30	3892	8	69
	t1.5_1	375	5	3	281	3	2	2973	35	69	8397	32	335
	t1.5_2	395	4	3	375	4	3	6533	47	219	7386	29	230
	t2.5_1	565	14	16	486	7	4	5998	117	506	11122	78	662
	t2.5_2	662	14	15	443	9	6	9880	142	771	10034	50	502
ıke	t5.5_1	725	46	80	768	44	77	8066	162	1008	21521	316	2314
Uptake	t5.5_2	617	45	66	735	47	82	7933	244	1124	18018	173	1832
	t9.5_1	694	69	128	657	77	174	9943	336	2394	21270	446	3237
	t9.5_2	683	105	177	792	113	227	8800	467	2293	24340	432	3728
	t17.5_1	787	132	214	787	122	402	12345	572	5352	23996	899	6676
	t17.5_2	788	208	328	872	198	429	11593	723	5701	22448	870	6371
	t24_1	791	229	435	767	229	555	11519	612	5450	33353	1476	10526
	t24_2	748	165	303	782	162	543	11636	849	6889	22685	1239	8793
	t0_1	568	168	370	734	186	593	12106	688	7341	27075	1024	9201
	t0_2	456	169	317	868	165	519	11317	810	6631	24108	1090	8836
	t1_1	346	162	339	602	129	546	7587	465	4184	24107	948	8390
	t1_2	312	201	443	1048	169	571	8709	531	5705	20345	1157	9858
	t2_1	293	216	383	683	195	752	3755	654	4972	20931	1142	10465
	t2_2	287	215	318	648	174	538	4720	374	4064	18250	839	8069
	t4_1	238	161	290	589	107	565	2145	474	4041	13888	632	6533
	t4_2	217	102	197	520	126	558	3411	431	3535	22298	1544	12654
	t7_1	166	54	113	466	129	412	803	338	2243	8943	954	9232
	t7_2	206	150	286	496	144	557	676	463	3463	10433	1142	10242
	t11_1	141	89	201	393	113	482	341	377	2705	5112	923	7934
ation	t11_2	183	94	239	459	94	508	1013	562	3618	7182	807	8479
Depuration	t18_1	118	41	122	323	110	419	168	384	2282	3610	1092	9172
	t18_2	126	86	239	336	61	392	155	28	1005	2995	769	6926
	t26_1	91	70	187	255	82	332	113	136	912	1067	558	5574
	t26_2	91	21	51	292	47	320	161	110	898	1160	622	4895
	t41_1	43	63	154	193	39	377	110	112	853	604	437	3818
	t41_2	45	46	138	158	45	223	106	14	488	453	706	5150
	t71_1	77	28	40	267	35	305	139	44	426	492	552	4011
	t71_2	21	7	4	60	13	53	280	60	727	700	518	4022
	t95_1	23	21	27	83	19	149	83	30	374	442	255	2522
	t95_2	34	31	93	63	25	158	58	62	386	304	204	2469
	t120_1	11	0	0	60	6	87	117	43	276	360	182	2110
	t120_2	22	11	22	52	15	82	74	23	333	341	148	1652

SI. G Lethal Concentrations of Azoxystrobin (LC50s) in the Presence and

Table S10: Used azoxystrobin concentration [μ g L⁻¹] for the determination of LC₅₀s of azoxystrobin in the presence and absence of prochloraz based on a range defining test.

Species	Treatment	azoxystrobin concentration [μg L ⁻¹]
	AZ	50, 100, 150, 200, 250, 300, 350
Gammarus pulex	$AZ + 0.37 \mu g L^{-1} PRZ$	50, 100, 150, 200, 250, 300, 350
	$AZ + 74 \mu g L^{-1} PRZ$	5, 15, 25, 35, 45, 55, 65
	AZ	50, 100, 150, 200, 250, 300, 400, 500, 600
Hyalella azteca	$AZ + 0.37 \mu g L^{-1} PRZ$	50, 100, 150, 200, 250, 300, 400, 500, 600
	$AZ + 74 \mu g L^{-1} PRZ$	25, 35, 45, 55, 65, 75, 85, 95, 105

SI. H Exposure Medium Concentrations, Internal Concentrations and Bioaccumulation Factors (BAFs) for *H. azteca*

Tables in this section are sorted according to the order of the experiments in the *Materials and Methods*. BAFs reported in this section are based on the ratio of the concentration of the parent compound in the organisms and of the concentration of the parent compound in the exposure medium with the requirement of steady state (see equation 4 in the corresponding publication). t_0 refers to the addition of the substrate and t_{24} to the end of the exposure phase.

The following abbreviations are valid for all tables located in this section:

m: medium samples

C+ cg-: "chemical controls" (organism and cotton gauze negative, chemical positive)

C+ cg+: "food controls" (organism negative, cotton gauze and chemical positive)

AZ: azoxystrobin

PRZ: prochloraz

Table S11: Biotransformation screening experiment in *H. azteca*: exposure to 100 μ g L⁻¹ AZ and PRZ, respectively. In the control samples nominal concentrations of 100 μ g L⁻¹ AZ and PRZ, respectively, were used.

Measured concentration in exposure medium							
	AZ [μg L ⁻¹]	AZ [nmol L ⁻¹]	PRZ [µg L ⁻¹]	PRZ[nmol L ⁻¹]			
m_C+ cg- t0_1	98		96				
m_C+ cg- t0_2	96		95				
m_C+ cg- t24_1	102		98				
m_C+ cg- t24_2	102		100				
m_C+ cg+ t0_1	92		84				
m_C+ cg+ t0_2	100		93				
m_C+ cg+ t24_1	101		91				
m_C+ cg+ t24_2	98		89				
m_AZ t0_1	101	252					
m_AZ t0_2	96	239					
m_AZ t24_1	97	240					
m_AZ t24_2	89	222					
m_PRZ t0_1			101	269			
m_PRZ t0_2			100	265			
m_PRZ t24_1			81	216			
m_PRZ t24_2			91	243			

Whole body internal concentration 24 h after substrate addition and corresponding BAFs

	AZ [nmol kgww -1]	BAF AZ [L kg _{ww} -1]	PRZ [nmol kg _{ww} ⁻¹]	BAF PRZ [L kg _{ww} -1]
AZ_1	890	4		
AZ_2	901	4		
PRZ_1			9413	39
PRZ_2			10793	42

Table S12: Toxicokinetic experiment in *H. azteca*: exposure to 80 μ g L⁻¹ AZ in the uptake phase. In the control samples nominal concentrations of 80 μ g L⁻¹ AZ were used.

Measured concentration in exposure medium					
	AZ [μg L ⁻¹]	AZ [nmol L ⁻¹]			
m_C+ cg- t0_1	77				
m_C+ cg- t0_2	77				
m_C+ cg- t24_1	78				
m_C+ cg- t24_2	80				
m_C+ cg+ t0_1	82				
m_C+ cg+ t0_2	78				
m_C+ cg+ t24_1	82				
m_C+ cg+ t24_2	75				
m_AZ t0_1	71	177			
m_AZ t0_2	79	195			
m_AZ t24_1	77	191			
m_AZ t24_2	78	193			
m_AZ t0_1*)	76	189			
m_AZ t0_2*)	78	194			
m_AZ t24_1*)	80	199			
m_AZ t24_2*)	81	201			

Whole body internal concer	Whole body internal concentrations 24 h after substrate addition and corresponding BAFs				
	AZ [nmol kgww ⁻¹]	BAF AZ [L kgww ⁻¹]			
AZ_Ut24_1	767	4			
AZ_Ut24_2	782	4			
AZ_Dt0_1	734	4			
AZ_Dt0_2	868	5			

^{*)} Uptake phase for following depuration experiment.

Table S13: Toxicokinetic experiment in *H. azteca*: exposure to 80 μ g L⁻¹ PRZ in the uptake phase. In the control samples nominal concentrations of 80 μ g L⁻¹ PRZ were used.

Measured concentration in	1 exposure medium	
	PRZ [μg L ⁻¹]	PRZ [nmol L ⁻¹]
m_C+ cg- t0_1	88	
m_C+ cg- t0_2	98	
m_C+ cg- t24_1	89	
m_C+ cg- t24_2	95	
m_C+ cg+ t0_1	94	
m_C+ cg+ t0_2	90	
m_C+ cg+ t24_1	98	
m_C+ cg+ t24_2	96	
m_PRZ t0_1	92	244
m_PRZ t0_2	92	245
m_PRZ t24_1	88	234
m_PRZ t24_2	90	240
m_PRZ t0_1*)	98	262
m_PRZ t0_2*)	90	242
m_PRZ t24_1*)	93	247
m_PRZ t24_2*)	93	249

Whole body internal concentrations 24 h after substrate addition and corresponding BAFs				
	PRZ [nmol kgww ⁻¹]	BAF PRZ [L kgww ⁻¹]		
PRZ_Ut24_1	33353	116		
PRZ_Ut24_2	22685	143		
PRZ_Dt0_1	27075	100		
PRZ_Dt0_2	24108	94		

^{*)} Uptake phase for following depuration experiment.

Table S14: Exposure and whole body concentrations of the experiment on Half-maximal inhibitory concentration of PRZ in *H. azteca* using AZ as a substrate (IC_{50, PRZ, AZ}). Exposure to 40 μ g L⁻¹ AZ and varying PRZ concentrations of c1 = 0.19 μ g L⁻¹, c2 = 0.37 μ g L⁻¹, c3 = 0.74 μ g L⁻¹, c4 = 3.7 μ g L⁻¹, c5 = 7.4 μ g L⁻¹, c6 = 22 μ g L⁻¹, c7 = 37 μ g L⁻¹, c8 = 74 μ g L⁻¹ and c9 = 372 μ g L⁻¹ (18 h pre-exposure to PRZ). In the control samples nominal concentrations of 40 μ g L⁻¹ AZ and 37 μ g L⁻¹ PRZ were used.

Exposure medium			
	AZ [μg L ⁻¹]	AZ [nmol L ⁻¹]	PRZ [μg L ⁻¹]
m_C+ cg1 (t0 PRZ)			36
m_C+ cg2 (t0 PRZ)			36
m_C+ cg- t0_1	39		35
m_C+ cg- t0_2	40		36
m_C+ cg- t24_1	38		34
m_C+ cg- t24_2	40		35
m_C+ cg+_1 (t0 PRZ)			37
m_C+ cg+_2 (t0 PRZ)			36
m_C+ cg+ t0_1	38		36
m_C+ cg+ t0_2	39		37
m_C+ cg+ t24_1	38		34
m_C+ cg+ t24_2	38		36
$m_AZ + PRZ c1_1 (t0 PRZ)$			0.2
$m_AZ + PRZ c1_2 (t0 PRZ)$			0.2
$m_AZ + PRZ c2_1 (t0 PRZ)$			0.4
$m_AZ + PRZ c2_2 (t0 PRZ)$			0.4
$m_AZ + PRZ c3_1 (t0 PRZ)$			0.7
$m_AZ + PRZ c3_2 (t0 PRZ)$			0.7
$m_AZ + PRZ c4_1 (t0 PRZ)$			3
$m_AZ + PRZ c4_2 (t0 PRZ)$			3
$m_AZ + PRZ c5_1 (t0 PRZ)$			7
$m_AZ + PRZ c5_2 (t0 PRZ)$			7
$m_AZ + PRZ c6_1 (t0 PRZ)$			20
$m_AZ + PRZ c7_1 (t0 PRZ)$			34
$m_AZ + PRZ c7_2 (t0 PRZ)$			35
$m_AZ + PRZ c8_1 (t0 PRZ)$			68
$m_AZ + PRZ c8_2 (t0 PRZ)$			69
$m_AZ + PRZ c9_1 (t0 PRZ)$			358
$m_AZ + PRZ c9_2 (t0 PRZ)$			339
m_AZ t0_1	39	97	
m_AZ t0_2	40	99	
$m_AZ + PRZ c1 t0_1$	37	92	0.4
$m_AZ + PRZ c1 t0_2$	37	92	0.4
m_AZ + PRZ c2 t0_1	39	98	0.5
m_AZ + PRZ c2 t0_2	38	94	0.5
m_AZ + PRZ c3 t0_1	38	93	0.8
$m_AZ + PRZ c3 t0_2$	40	100	0.8

Exposure medium			
	$AZ [\mu g L^{-1}]$	AZ [nmol L ⁻¹]	PRZ [μg L ⁻¹]
m_AZ + PRZ c4 t0_2	40	98	3
m_AZ + PRZ c5 t0_1	39	97	7
m_AZ + PRZ c5 t0_2	41	101	8
m_AZ + PRZ c6 t0_1	41	102	20
m_AZ + PRZ c6 t0_2	40	100	21
m_AZ + PRZ c7 t0_1	38	95	34
m_AZ + PRZ c7 t0_2	38	95	35
m_AZ + PRZ c8 t0_1	38	94	70
m_AZ + PRZ c8 t0_2	39	98	68
m_AZ + PRZ c9 t0_1	41	103	353
m_AZ + PRZ c9 t0_2	41	102	348
m_AZ t24_1	37	92	
m_AZ t24_2	39	97	
m AZ + PRZ c1 t24 1	38	94	0.3
m AZ + PRZ c1 t24 2	38	94	0.3
m AZ + PRZ c2 t24 1	39	98	0.4
m AZ + PRZ c2 t24 2	39	96	0.4
m AZ + PRZ c3 t24 1	38	94	0.8
m AZ + PRZ c3 t24 2	41	101	0.8
m AZ + PRZ c4 t24 1	37	91	3
m_AZ + PRZ c4 t24_2	41	101	3
m AZ + PRZ c5 t24 1	38	95	7
m AZ + PRZ c5 t24 2	40	99	7
m_AZ + PRZ c6 t24_1	40	100	19
m AZ + PRZ c6 t24 2	39	98	19
m AZ + PRZ c7 t24 1	38	95	33
m AZ + PRZ c7 t24 2	39	97	33
m AZ + PRZ c8 t24 1	38	93	65
m AZ + PRZ c8 t24 2	40	98	67
m AZ + PRZ c9 t24 1	38	94	338
m AZ + PRZ c9 t24 2	42	104	355
Whole body internal concer	ntrations 24 h after sub	ostrate addition and c	
		BAF AZ [L kgww ⁻¹]	
AZ_1	781	8	
AZ_2	703	7	
AZ_3	792	8	
$AZ + PRZ c1_1$	710	8	54
$AZ + PRZ c1_2$	769	8	52
$AZ + PRZ c2_1$	750	8	127
$AZ + PRZ c2_2$	743	8	113
	713	7	211

Whole body internal concentrations 24 h after substrate addition and corresponding BAFs					
	AZ [nmol kg _{ww} -1]	BAF AZ [L kg_{ww}^{-1}]	$PRZ \ [nmol \ kg_{ww}^{-1}]$		
AZ + PRZ c3_2	834	9	221		
$AZ + PRZ c4_1$	770	8	1107		
$AZ + PRZ c4_2$	838	9	1129		
$AZ + PRZ c5_1$	802	8	3158		
$AZ + PRZ c5_2$	776	8	2243		
$AZ + PRZ c6_1$	888	9	6720		
$AZ + PRZ c6_2$	867	9	6496		
$AZ + PRZ c7_1$	927	10	10937		
$AZ + PRZ c7_2$	887	9	11245		
$AZ + PRZ c8_1$	1095	11	20921		
$AZ + PRZ c8_2$	1149	12	22851		
$AZ + PRZ c9_1$	1183	12	77899		
$AZ + PRZ c9_2$	1151	11	67027		

SI. I Determination of IC_{50, PRZ, AZ}s in *H. azteca*




Figure S4: Whole body internal concentration of azoxystrobin and its BTPs after 24 h exposure to $40~\mu g~L^{-1}$ azoxystrobin: 18 h pre-exposure without chemical in black (sample replicates n=3) and 18 h pre-exposure to varying prochloraz (PRZ) concentrations (n=2) (c1: 0.19, c2: 0.37, c3: 0.74, c4: 3.7, c5: 7.4, c6: 22, c7: 37, c8: 74 and c9: 372 $\mu g~L^{-1}$) in red. The filled areas mark the parent compound azoxystrobin, whereas the hatched areas mark the sum of all detected BTPs. Total internal concentrations in each mixture were compared to those of the controls (single exposure to azoxystrobin) with a t-test (two tailed distribution, two-sample equal variance) and showed statistical difference for treatment PRZ c8 and PRZ c9 (p < 0.05) marked with an asterisk.

SI. J Dose-Response Fitting of IC_{50, PRZ, AZ}s in *H. azteca*

The log-logistic four-parameter model (LL.4) used for the fitting of dose-response curves is available in the R⁸ package "drc" from Ritz and Streibig (2005)⁹ and is described by the following equation:

Log-logistic four-parameter model (LL.4):

$$f(x) = c + \frac{d - c}{1 + \exp(b(\log(x) - \log(e)))}$$
 equation S2

where d and c are the upper and lower limits of response, respectively, b denotes the relative slope in the infliction point, e is the infliction point and thereby the EC₅₀, and x is the prochloraz concentration.




Figure S5: Dose-response curves for the $IC_{50/10,\,PRZ,\,AZ}$ determination based on whole body internal concentration measurements of azoxystrobin and its BTPs (shown are the two primary BTPs AZ_M390a and AZ_M214). Internal concentrations of azoxystrobin and its BTPs were measured after 24 h exposure to 40 μ g L⁻¹ azoxystrobin. Controls were pre-exposed without chemical for 18 h, whereas treatments where pre-exposed for 18 h to varying prochloraz concentrations (c1: 0.19, c2: 0.37, c3: 0.74, c4: 3.7, c5: 7.4, c6: 22, c7: 37, c8: 74 and c9: 372 μ g L⁻¹).

Table S15: Estimated parameters (d: upper limit of response; c: lower limit of response; b: relative slope in the infliction point; e: infliction point and thereby the $IC_{50,\,PRZ,\,AZ}$) and determined $IC_{50/10,\,PRZ,\,AZ}$ s for azoxystrobin and primary BTPs with the four-parameter log-logistic mode in *H. azteca*. Parameters and $IC_{50/10,\,PRZ,\,AZ}$ s are reported with the corresponding standard errors. Measured internal concentrations of AZ_M214 exhibited large variations (see Figure S5 above). Therefore, $IC_{50/10,\,AZ,\,PRZ}$ s based on the dose response curve of AZ M214 have to be treated with care.

	b		d	e, IC _{50, PRZ, AZ}	e, IC _{50, PRZ, AZ}	IC _{10, PRZ, AZ}	IC _{10, PRZ, AZ}
	D	c	u	[μΜ]	[μg L ⁻¹]	[μΜ]	$[\mu g \ L^{-1}]$
Azoxystrobin	-2.24	101	156	0.111	41.7	0.0416	15.6
	± 0.686	± 1.73	± 4.09	± 0.0144	± 5.39	± 0.0134	± 5.01
AZ_M390b	2.78	-0.0557	88.7	0.0970	36.4	0.0440	16.5
A2_N3500	± 1.41	± 13.1	± 5.43	± 0.0234	± 8.76	± 0.0173	±6.47
AZ_M214	2.73	-3.29	117	0.0472	17.7	0.0211	7.91
AZ_W1214	± 2.28	± 24.1	± 14.7	± 0.0264	± 9.92	± 0.0217	± 8.15

A "Lack-of-fit-F-test" with the "anova function" available in the R⁸ package "drc" from Ritz and Streibig (2005)⁹ was performed to test if there is statistical difference between the dose-response curves fitted to the internal concentrations of azoxystrobin and AZ_M390b, respectively, in *H. azteca* and *G. pulex*. It was tested if the reduction from a larger to a smaller model is statistically justified. Therefore, first, both datasets (data of azoxystrobin or AZ_M390b, respectively, of the two test species) are fitted into one model together but with individual parameters for the log-logistic four parameter model for each dataset. Second, both datasets are fitted into one model with similar parameters for the log-logistic four parameter model.

The calculated p-values showed that there is statistical difference between the dose response curves for azoxystrobin (p < 0.0059) and AZ_M390b (p < 0.0130), respectively, for the two test species.

Table S16: The LC_{50} and benchmark dose (BMD₅) of azoxystrobin in the absence and presence of prochloraz observed in *H. azteca* and *G. pulex*

Indicators	Azoxystrobin	Azoxystrobin + 0.2μM prochloraz	Fold change
H. azteca	(nM)	(nM)	
LC ₅₀	500	200	2.5
BMD_5	376 102		3.7
$BMDL_5$	299	19	15.7
$BMDU_5$	689	135	5.1
G. pulex			
LC_{50}	400	100	4.0
BMD_5	246	55	4.5
$BMDL_5$	136	16	8.5
$BMDU_5$	383	73	5.2

 LC_{50} : median lethal concentration. BMD, benchmark dose, BMDL, lowest benchmark dose lower bound from exponential models; BMDU, highest benchmark dose upper bound Hill models; The subscripted number means the benchmark response, i.e. 5%, used when calculating BMD.

SI. K Distance moved (cm) of the Video-Tracking of *G. pulex* and *H. azteca* during 18 h prochloraz exposure

Species	Concentration of prochloraz in exposure medium					
	0 μΜ	0.02 μΜ	0.1 μΜ	0.2 μΜ	1 μΜ	2 μΜ
Hyalella azteca	3545 ± 4381	2304 ± 3247	2567 ± 3237	1910 ± 1968	4949 ± 9782	3673 ± 4950
Gammarus pulex	1159 ± 835	1668 ± 883*	2174 ± 1054*	1381 ± 998	1841 ± 1769*	864 ± 543

Protocol for *G. pulex* is described in Rösch et al ⁴. *H. azteca* were placed in 6 well plate with 5 ml per well and recorded for 18 hours. Distance moved was calculated for each animal. Asterisks indicate treatment samples that are significantly different from the control.

SI. L Comparison of different *H. azteca* Sample Wet Weights for Detection and Quantification of Biotransformation Products

Measuring internal concentrations at different time points during the uptake and depuration phase requires the use of plenty of test organisms (~2000 organisms if one sample is composed of 50 organisms). Therefore, reducing the amount of organisms was tried. For the *H. azteca* screening experiment (exposure to 100 μg L⁻¹ azoxystrobin) the same sample wet weight as applied in the *G. pulex* bioaccumulation and biotransformation experiments was used (~130 mg which relate to 4 *G. pulex* or 50 *H. azteca*). Additionally, a reduced wet weight of ~70 mg (30 *H. azteca*) with similar exposure concentrations was tested to evaluate if a decreased wet weight is sufficient in terms of LOQs of BTPs (see SI. B). All BTPs of azoxystrobin were still detected in the extracts of the reduced sample wet weight. However, the sulfate-containing BTPs are more sensitive during negative electrospray ionization but have to be quantified in positive ionization mode since their quantification is based on the parent compound, which is only detectable in positive ionization mode. Therefore, two sulfate-containing BTPs (AZ_M514 and AZ_M618) that already displayed very low intensities using ~130 mg wet weight, could no longer be quantified. The loss of two minor BTPs was considered acceptable in the light of reducing the number of test organisms and the kinetic experiment was carried out with the reduced wet weight.

SI. M Identified Biotransformation Products for Azoxystrobin and Prochloraz in H. azteca

Table S17: Overview of azoxystrobin and identified biotransformation products formed in the aquatic invertebrate *H. azteca*. Biotransformation products are listed according to their relative peak intensity. Information about mass error and retention time (RT) are given for both replicate samples. CE stands for collision energy applied for fragmentation in the MS/MS experiment. Below each biotransformation product the abbreviation (S) stands for "identified by suspect screening (S)", whereas (N) stands for "identified by nontarget" screening. The abbreviation (H) stands for BTPs that were only identified in *H. azteca* and not in *G. pulex*. (H‡) stands for BTPs that were afterward identified in G. pulex, but with intensities below the set threshold of 1E6. The mass error of all identified BTPs was < 3ppm.

	act mass of [+H] ⁺ / [M-H] ⁻			change iv)		confidence "			confirmatory
	, , ,			5		confidence vi) /level according to Schymanski et al. (2014) ⁶ / vii)		[eV]	ions viii)
Azoxystrobin C ₂₂ 1	$_{2}H_{17}N_{3}O_{5}$	14.6	+		4.2	/1/	parent compound	15	
ET270001 404	4.1241	14.6							
H ₃ C N N N									
BAF [L kg_{ww}^{-1}] at t_{24}^{i} : 4; 4									
BAF _k [L kg _{ww} ⁻¹] ⁱⁱ⁾ : 6									
AZ_M638 (H) C ₃₀ l	$_{0}H_{27}O_{13}N_{3}$	12.7	+	- CH ₂	-1.3	d, p	demethylation,	20	390.1083
ET273401 638	8.1617	12.7		$+ C_6H_{10}O_5$		/3/, most likely structure	glucose conjugation,		358.0821
(N)				$+ C_3H_2O_3$			malonyl conjugation		302.0916
AZ_M640 (H) C ₃₀ l	$_{0}H_{29}O_{13}N_{3}$	13.0	+	- CH ₂	-1.8	d, p	demethylation,	20	392.1239
ET273301 640	0.1773	13.0		+ H ₂		/3/, most likely structure	hydrogenation,		342.0872
(N)				$+ C_6H_{10}O_5$			glucose conjugation,		360.0979
				$+ C_3H_2O_3$			malonyl conjugation		

Compound	Formula [M]	RT [min] iii)	Polarity	Elemental change ^{iv)}	Log Dow v)	Identification confidence vi)	Description	CE [eV]	MS/MS confirmatory
MassBank ID of displayed MS/MS spectrum	Exact mass of [M+H] ⁺ /[M-H] ⁻			change		/level according to Schymanski et al. (2014) ⁶ / vii)		[ev]	ions viii)
AZ_M390a	$C_{21}H_{15}N_3O_5$	11.9	+	- CH ₂	3.5	D	demethylation	30	372.0979
ET273701	390.1084	11.7				/2b/			344.1031
(S)									329.0795
AZ_M390b	$C_{21}H_{15}N_3O_5$	13.6	+	- CH ₂	0.4	l ⁵⁻⁷	ester hydrolysis	30	372.0981
ET273801	390.1084	13.6				/1/			344.1032
(S)									302.0927
AZ_M497 (H)	$C_{23}H_{20}N_4O_7S$	11.5	+	- CH ₂	-0.1	d (in negative ionization	demethylation,	40	344.1031
ЕТ271902	497.1125	11.4		$+ C_2H_5NO_2S$		mode diagnostic taurine loss), p for conjugation	taurine conjugation		329.0795
(S)						of AZ_M390b			372.0979
						/2b/			
AZ_M392	$C_{21}H_{17}N_3O_5$	13.5	+	- CH ₂	0.1	l ⁵	ester hydrolysis,	15	342.0871
ET274601	392.1241	13.5		+ H ₂		p	hydrogenation		392.1238
(S)						/3/, most likely structure			360.0977
AZ_M630	$C_{27}H_{25}N_3O_{13}S$	11.7	- ^{ix)}	- CH ₂	-0.5	d, p	demethylation,	20	241.0024
ET273251	630.1035	11.6		$+ C_6H_{10}O_5$		/3/, most likely structure	glucose conjugation,		96.9601
(S)				+ SO ₃			sulfate conjugation		630.1038
AZ_M420	$C_{22}H_{17}N_3O_6$	11.2-14-5	+	+ O	3.6-3.7	p for hydroxylation at the	aliphatic hydroxylation	40	329.0796
ЕТ274902	420.1190	11.1-14.4				(<i>E</i>)-methyl β- methoxyacrylate group			360.0979
(S)						/3/, 3 positional isomers			316.1075

Compound	Formula [M]	RT [min] iii)	Polarity	Elemental change iv)	Log Dow v)	Identification confidence ^{vi)}	Description	CE	MS/MS confirmatory
MassBank ID of displayed MS/MS spectrum	Exact mass of [M+H] ⁺ / [M-H] ⁻			change		/level according to Schymanski et al. (2014) ⁶ / ^{vii)}		[eV]	ions viii)
AZ_M214	$C_{11}H_7N_3O_2$	7.9	+	- C ₁₁ H ₁₀ O ₃	2.3	D	ether cleavage	40	214.0610
ET274201	214.0611	7.9				l ⁵			187.0501
(S)									120.0442
AZ_M362b	$C_{20}H_{15}N_3O_4$	14.4	+	- C ₂ H ₂ O	0.8-2.8	d for C ₂ H ₂ O loss at the	- C ₂ H ₂ O	20	362.1135
ET274501	362.1135	14.5				(<i>E</i>)-methyl β- methoxyacrylate group			302.0922
(S)						$/3/$, ≥ 3 positional isomers			330.0872
AZ_M485 (H)	$C_{22}H_{20}N_4O_7S$	10.9	+	- C ₂ H ₂	-0.9	d, p for conjugation of	ester hydrolysis,	20	126.0220
ET272401	485.1125	10.8		+ H ₂		AZ_M390b	demethylation,		342.0875
(S)				$+ C_2H_5NO_2S$		/3/ most likely structure	hydrogenation,		467.1022
							taurine product		
AZ_M378	$C_{20}H_{15}N_3O_5$	12.4	+	- C ₂ H ₂	-0.5	D	hydrogenation,	15	378.1082
ET274102	378.1084	12.4				/2b/	didemethylation,		342.0872
(S)									360.0972
AZ_M552	$C_{27}H_{25}N_3O_{10}$	12.4	+	- CH ₂	1.8	d, p	demethylation,	15	358.0822
ЕТ273904	552.1613	12.4		$+ C_6 H_{10} O_5$		/3/, most likely structure	glucose conjugation		390.1085
(S)									552.1632
AZ_M541 (H)	$C_{25}H_{24}N_4O_8S$	11.0	+	+ O	0.5	d, p	aliphatic hydroxylation,	20	491.1020
ET272201	541.1388	11.1		$+ C_3H_7NO_2S$		/3/, 3 positional isomers	cysteine product		388.0923
(S)									328.0852

Compound MassBank ID of displayed MS/MS spectrum	Formula [M] Exact mass of [M+H] ⁺ / [M-H] ⁻	RT [min] ⁱⁱⁱ⁾	Polarity	Elemental change ^{iv)}	Log D _{ow} v)	Identification confidence vi) /level according to Schymanski et al. (2014) ⁶ / vii)	Description	CE [eV]	MS/MS confirmatory ions ^{viii)}
AZ_M436 (H‡)	$C_{22}H_{17}N_3O_7$	12.0	+	+ O	≈1.9-3.9	d, p for only one hydroxylation at the (<i>E</i>)-	aliphatic hydroxylation,	60	304.0721
(S)	436.1139	12.0		+ O		methyl β-methoxy-	hydroxylation		215.0452
ET272303						acrylate group			361.0691
AZ_M632 (H)	$C_{27}H_{27}N_3O_{13}S$	12.0	_ ix)	- CH ₂	-1.0	d, p	demethylation,	40	241.0024
ET272952	632.1192	11.8		+ H ₂		/3/, most likely structure	hydrogenation,		96.9600
(S)				$+ C_6H_{10}O_5$			glucose conjugation,		632.1190
				+ SO ₃			sulfate conjugation,		
AZ_M554a (H)	$C_{27}H_{27}N_3O_{10}$	11.9	+	- CH ₂	1.4	p	demethylation,	20	392.1241
ET272001	554.1769	11.8		+ H ₂		/3/, most likely structure	hydrogenation,		342.0875
(S)				$+ C_6 H_{10} O_5$			glucose conjugation		360.0979
AZ_M684 (H)	$C_{31}H_{29}O_{15}N_3$	11.7	+	+ O	\approx -0.9 to -3	p	aliphatic hydroxylation,	20	634.1296
ET273501	684.1671	11.7		+ O		/3/, many positional	hydroxylation,		652.1418
(N)				$+ C_6H_{10}O_5$		isomers	glucose conjugation,		404.0873
				$+ C_3H_2O_3$			malonyl conjugation		
AZ_M362a	$C_{20}H_{15}N_3O_4$	13.6	+	- C ₂ H ₂ O	0.8-2.8	d for C ₂ H ₂ O loss at the	- C ₂ H ₂ O	20	362.1136
ET274403	362.1135	13.5				(E)-methyl β-methoxy- acrylate group			330.0873
(S)						$/3/, \ge 3$ positional isomers			302.0921
AZ_M660 (H‡)	$C_{28}H_{27}O_{14}N_3S$	11.2	+	+O	-0.1 to -0.5	d, p	aliphatic hydroxylation,	20	420.1190
ET273601	660.1141	11.1		$+ C_6H_{10}O_5$		/3/, 3 positional isomers	glucose conjugation,		205.1073
(S)				+ SO ₃			sulfate conjugation,		550.1457

Compound	Formula [M]	RT [min] iii)	Polarity	Elemental	Log D _{ow} v)	Identification confidence vi)	Description	CE	MS/MS
MassBank ID of displayed MS/MS spectrum	Exact mass of [M+H] ⁺ / [M-H] ⁻			change ^{iv)}		/level according to Schymanski et al. (2014) ⁶ / ^{vii)}		[eV]	confirmatory ions ^{viii)}
AZ_M513 (H)	$C_{23}H_{20}N_4O_8S$	11.4	+	- CH ₂	-0-7 to 0.1	d, p for taurine loss and	demethylation,	20	356.0666
ET272701	513.1074	11.3		+ O		conjugation of AZ_M390b	aliphatic hydroxylation,		513.1076
(S)				+ C ₂ H ₅ NO ₂ S		/3/ 2 positional isomers	taurine conjugation		481.0806
AZ_M554b (H)	$C_{27}H_{27}N_3O_{10}$	12.8	+	- CH ₂	1.4	p	demethylation,	20	392.1239
ET272101	554.1769	12.8		+ H ₂		/3/, most likely structure	hydrogenation,		342.0875
(S)				$+ C_6H_{10}O_5$			glucose conjugation		360.0979
AZ_M582b (H)	$C_{28}H_{27}N_3O_{11}$	13.2	+	+ O	1.9-2.2	d , p for hydroxylation	aliphatic hydroxylation,	15	145.0492
ET272604	582.1718	13.2		$+ C_6H_{10}O_5$		and glucose conjugation at the (E) -methyl β -	glucose conjugation		334.1185
(S)						methoxyacrylate group			316.1089
						/3/, 3 positional isomers			
AZ_M582a (H)	$C_{28}H_{27}N_3O_{11}$	11.2	+	+ O	1.9-2.2	p for hydroxylation and	aliphatic hydroxylation,	15	550.1453
ET272501	582.1718	11.1		$+ C_6 H_{10} O_5$		glucose conjugation at the (E)-methyl β -meth-	glucose conjugation		388.0932
(S)						oxyacrylate group			420.1190
						/3/, 3 positional isomers			
AZ_M498	$C_{22}H_{17}N_3O_9S$	11.4	- ix)	+ O	1.3-1.7	p for hydroxylation and	aliphatic hydroxylation,	15	498.0614
ET273152	498.0613	11.3		+ SO ₃		sulfate conjugation at the (E) -methyl β -	sulfate conjugation		418.1045
(S)						methoxyacrylate group			358.0818
						/3/, 3 positional isomers			
AZ_M493	$C_{24}H_{20}N_4O_6S$	12.9-14.0	+	- CH ₄ O	1.2-1.3	d, p	- CH ₄ O,	20	132.0115
ET274303	493.1176			$+ C_3H_7NO_2S$		/3/, most likely structures	cysteine product		330.0869
(S)									461.0911

Compound MassBank ID of displayed MS/MS spectrum	Formula [M]	RT [min] iii)	Polarity	Elemental change ^{iv)}	Log D _{ow} v)	Identification confidence vi)	Description	CE [eV]	MS/MS confirmatory
	Exact mass of [M+H] ⁺ / [M-H] ⁻					/level according to Schymanski et al. (2014) ⁶ / ^{vii)}		[ev]	ions viii)
AZ_M618	$C_{26}H_{25}N_3O_{13}S$	11.2	- ix)	- CH ₂	-4.6	d, p	demethylation,	20	241.0025
ЕТ273052	618.1035	11.1		$+ C_6 H_{10} O_5$		/3/, most likely structure	glucose conjugation,		618.1044
(S)				+ SO ₃			sulfate conjugation,		96.9601
				- CH ₂			ester hydrolysis,		
				+ H ₂			hydrogenation		
AZ_M525	$C_{25}H_{24}N_4O_7S$	12.5-13.3	+	+ C ₃ H ₇ NO ₂ S	1.1	p	cysteine product	20	372.0980
ET274005	525.1438	12.5-13.4				/3/, most likely structure			330.0870
(S)									461.0893
AZ_M514	$C_{22}H_{17}N_3O_{10}S$	11.2	- ix)	+ O	-0.8-2.0	d for only one	aliphatic hydroxylation,	20	359.0535
ET272851	514.0562	11.1		+ O		hydroxylationat the (E) - methyl β -methoxy-	hydroxylation,		434.1000
(S)				+ SO ₃		acrylate group	sulfate conjugation		514.0580
						p for hydroxylation and sulfate conjugation at the (<i>E</i>)-methyl β-methoxyacrylate group			
						/3/ many positional isomers			

Explanations to Table S17:

i) See Equation 4 in the corresponding publication for the calculation of BAFs at steady state.

 $^{^{}ii)}$ See Equation 5 in the corresponding publication for the calculation of kinetic BAF $_k$ s.

iii) In case of a retention time range, several possibly positional isomers were integrated as one peak, due to bad peak separation.

iv) The elemental change refers to the change in the molecular formula of the biotransformation product in comparison with the parent compound.

 $^{^{}y)}$ Log D_{ow} values were predicted by MarvinSketch version 14.10.20.0 at pH 7.9 and 25 °C. Log D_{ow} values correspond to corrected log K_{ow} values to account for pH-dependent dissociation. At pH 7.9 azoxystrobin is neutral thus log D_{ow} is equal to log K_{ow} . If different positional isomers are possible for one BTP, a range of log D_{ow} values is given.

vi) D: diagnostic fragment/evidence for one structure; d: diagnostic fragment/evidence for positional isomers; l: structure reported in literature; m: MS/MS data from literature; p: biotransformation pathway information; d, p: diagnostic fragment for positional isomers (d) in combination with pathway information (p) give evidence for one possible structure.

vii) Levels are defined as follows: 5 (exact mass), 4 (unequivocal molecular formula), 3 (tentative candidates: e.g., positional isomers), 2 (probable structure: library spectrum match (a) or diagnostic evidence for one structure (b)) and 1 (confirmed structure).

viii) Diagnostic fragments (d, D) are listed first and are represented in bold in the table, other characteristic fragments are then presented according to their relative abundance. Only fragments where a chemical formula and structure could be attributed are considered.

is) The sulfate-containing BTPs are more sensitive in negative ionization mode. However, they were quantified in positive ionization mode because azoxystrobin was detected and quantified in positive ionization mode.





Figure S6: Proposed biotransformation pathway of azoxystrobin in *G. pulex* and *H. azteca* based on the validated biotransformation pathway of *G. pulex*. Structural modifications of the BTPs are highlighted in red. BTPs written in black were detected in both species, whereas BTPs written in green are specific for *G. pulex* and BTPs written in blue are specific for *H. azteca*. Superscript text after italic written BTPs marks BTPs that were either not detected in the kinetic experiments (k) or not detected in the inhibition experiments (i, IC_{50, PRZ, AZ}) of *G. pulex* (G) or *H. azteca* (H) but in the BTP screening experiment.


The color and shape of the arrows distinguishes between biotransformation reaction types and test species (blue: *H. azteca*, green: *G. pulex*): continuous: reaction influenced by prochloraz; dashed: reaction influenced by prochloraz only due to previous reactions being influenced by prochloraz; continuous with circle: reaction not influenced by prochloraz; continuous light blue: no information on influence of prochloraz for *H. azteca*. The small blue stars located at the arrowhead of the prochloraz influenced biotransformation reaction towards the BTPs AZ_M392 and AZ_M378 for *H. azteca* mark the unexpected increase in internal concentrations of AZ_M392 and AZ_M378 with increasing prochloraz concentration.

[‡]) AZ_M554 is actually characterized by two low intensity peaks but it is unclear whether AZ_M554 is additionally formed out of AZ_M390b.


The different MassBank IDs for one compound refer to different collision energies applied during MS/MS fragmentation. The MassBank ID displayed in bold indicates the depicted MS/MS spectrum. Spectra are also available electronically in the MassBank database. ¹⁰

Azoxystrobin (AZ) MassBank ID: ET270001






AZ_M638




AZ_M640


MassBank ID: **ET273501**, ET273502, ET273503, ET273504




AZ_M390a MassBank ID: ET273701




AZ_M390b MassBank ID: ET273801




AZ_M497MassBank ID: ET271901, **ET271902**, ET271903, ET271904




AZ_M392 MassBank ID: ET274601



AZ_M630 MassBank ID: ET273251




AZ_M420 MassBank ID: ET274902





AZ_M214 MassBank ID: ET274201






AZ_M362b MassBank ID: ET274501







AZ_M485MassBank ID: **ET272401**, ET272402, ET272403, ET272404




AZ_M378 MassBank ID: ET274102




AZ_M552 MassBank ID: ET273904






AZ_M541

MassBank ID: **ET272201**, ET272202, ET272203, ET272204




AZ_M436

— MassBank ID: ET272301, ET272302, **ET272303**, ET272304




AZ_M632

MassBank ID: ET272951, ET272952, ET272953, ET272954




AZ_M554a


MassBank ID: **ET272001**, ET272002, ET272003, ET272004



AZ_M684MassBank ID: **ET273501**, ET273502, ET273503, ET273504




AZ_M362a





AZ_M660

MassBank ID: **ET273601**, ET273602, ET273603, ET273604





AZ_M513MassBank ID: **ET272701**, ET272702, ET272703, ET272704






AZ_M554bMassBank ID: **ET272101**, ET272102, ET272103, ET272104







AZ_M582b MassBank ID: ET272604




AZ_M582a MassBank ID: ET272501




AZ_M498 MassBank ID: ET273152




AZ_M493 MassBank ID: ET274303




AZ_M618MassBank ID: ET273051, **ET273052,** ET273053, ET273054



AZ_M525



AZ_M514MassBank ID: **ET272851**, ET272852, ET272853, ET272854






Table S18: Overview of prochloraz and identified biotransformation products formed in the aquatic invertebrate *H. azteca*. Biotransformation products are listed according to their relative peak intensity. Information about mass error and retention time (RT) are given for both replicate samples. CE stands for collision energy applied for fragmentation in the MS/MS experiment. Below each biotransformation product the abbreviation (S) stands for "identified by suspect screening (S)", whereas (N) stands for "identified by nontarget" screening. The abbreviation (H) stands for BTPs that were only identified in *H. azteca* and not in *G. pulex*. (H‡) stands for BTPs that were identified afterward in *G. pulex*, but with intensities below the set threshold of 1E6. The asterisk marks biotransformation products where the active azole moiety was altered. The mass error of all identified BTPs was < 3ppm.

Compound MassBank ID of displayed MS/MS spectrum	Formula [M] Exact mass of [M+H] ⁺ / [M-H] ⁻	RT [min] iii)	Polarity	Elemental change ^{iv)}	Log D _{ow} v)	Identification confidence ^{vi)} /level according to	Description	CE [eV]	MS/MS confirmatory ions viii)
						Schymanski et al. (2014) ¹¹ / _{vii)}			
Prochloraz (PRZ)	C ₁₅ H ₁₆ Cl ₃ N ₃ O ₂	16.3	+		3.6	/1/	parent compound	30	308.0006
ET200001	376.0381	16.3							70.0288
CI CH5									265.9536
BAF [L kg _{ww} ⁻¹] at t ₂₄ ⁱ⁾ : 110									
BAF _k [L kg _{ww} ⁻¹] ⁱⁱ⁾ : 117									
PRZ_M353 *	$C_{13}H_{15}Cl_3N_2O_3$	17.0	+	- C ₂ HN	3.4	D	partial loss of hydroxylated	30	308.0007
ET202601	353.0221	17.0		+ O		p	imidazole ring,		70.0288
(S)						l ^{12–14}	aldehyde formation		265.9536
						m ¹²			
						/2b/			
PRZ_M325 *	$C_{12}H_{15}Cl_3N_2O_2$	17.1	+	- C ₃ HN	3.4	D	partial loss of imidazole ring	35	282.0213
ET202701	325.0272	17.2				l ^{13–15}			325.0273
(S)						p			129.1022
						/1/			

Compound MassBank ID of displayed MS/MS spectrum	Formula [M]	RT [min] iii)	Polarity	Elemental change ^{iv)}	Log D _{ow} v)	Identification confidence vi)	Description	CE [eV]	MS/MS confirmatory ions viii)
	Exact mass of [M+H] ⁺ / [M-H] ⁻					/level according to Schymanski et al. (2014) ¹¹ / vii)			
PRZ_M558 * (H)	$C_{20}H_{26}Cl_3N_3O_7S$	16.7	+	- C ₃ H ₂ N ₂	-2.9	D	loss of imidazole ring,	20	308.0009
ET204901	558.0630	16.7		$+ C_{10}H_{15}N_3O_6S$		p	glutathione conjugation,		429.0207
(S)				- $C_2H_5NO_2$		/2b/ most likely structure	loss of glycine		558.0634
PRZ_M282 *	$C_{11}H_{14}Cl_3NO$	13.7	+	- C ₄ H ₂ N ₂ O	2.4	D	loss of imidazole ring and CO	30	282.0212
ET203201	282.0214	13.7				p			86.0964
(S)						/1/			72.0807
PRZ_M323b *	$C_{12}H_{12}Cl_3NO_3$	16.0	+	- C ₃ H ₄ N ₂	2.6-3.2	d for keto group at propyl	imidazole ring loss,	30	84.0808
ET202301	323.9956	16.0		+ O			aliphatic hydroxylation and further		128.0706
(S)						G. pulex, in H. azteca missing, most likely same position of aliphatic hydroxylation in H. azteca compared to G. pulex)	oxidation to a ketone		280.0057
PRZ_M239 *	C ₈ H ₈ Cl ₃ NO	12.8	+	- C ₇ H ₈ N ₂ O	1.4	D	remaining chlorophenyl moiety and	30	239.9743
ET202501	239.9744	12.8				/2b/	C ₂ H ₅ NO		222.9481
(S)									196.9315
PRZ_M392b *	$C_{15}H_{16}Cl_3N_3O_3$	15.4	+	+ O	2.3	d, p for hydroxylation at C-5	ring (possible	30	308.0006
ET202201	392.0330	15.4				in imidazole ring (possible epoxide formation at C4-C5			70.0287
(S)						as intermediate)			265.9535
						/3/, most likely structure			
PRZ_M435 *	C ₁₇ H ₂₁ Cl ₃ N ₄ O ₃	15.5	+	+ C ₂ H ₂ O	-	d for acetylation at CO-	acetylation at CO-imidazole ring	20	282.0212
(NH ₄ ⁺ adduct)	435.0752	15.5				imidazole ring moiety	moiety; NH ₄ ⁺ adduct		435.0750
ET203301						/3/, acetylation most likely at keto group			154.0610
(S)						- ·			

Compound MassBank ID of displayed MS/MS spectrum	Formula [M]	RT [min] iii)	Polarity	Elemental change ^{iv)}	Log D _{ow} v)	Identification confidence vi)	Description	CE [eV]	MS/MS confirmatory ions viii)
	Exact mass of [M+H] ⁺ / [M-H] ⁻					/level according to Schymanski et al. (2014) ¹¹ / vii)			
PRZ_M640 (H‡)	C ₂₄ H ₂₈ Cl ₃ N ₃ O ₁₁	11.7-14.4	+	+ O	-1.9 to -2.8	d, p	Hydroxylation at propyl side chain,	20	323.9958
ET204101	640.0862	(4 partly		$+ C_6H_{10}O_5$		/3/, most likely structure	glucose conjugation,		69.0449
(N)		separated peaks)		$+ C_3H_2O_3$			malonyl conjugation		128.9958
PRZ_M323a *	C ₁₂ H ₁₂ Cl ₃ NO ₃	15.7	+	- C ₃ H ₄ N ₂	2.6-3.2	d for keto group at propyl	imidazole ring loss,	30	84.0808
ET202401	323.9956	15.7		+ O		side chain (low intense diagnostic fragment in <i>G. pulex</i> , in <i>H. azteca</i> missing, most likely same position of aliphatic hydroxylation in <i>H. azteca</i> compared to <i>G. pulex</i>)	aliphatic hydroxylation and further		128.0706
(S)							oxidation to a ketone		280.0057
						/3/, 3 positional isomers			
PRZ_M382 *	$C_{14}H_{18}Cl_3N_3O_3$	16.6	+	- CH ₂	3.02	d, p for C-4 loss at	partial loss of hydroxylated	20	308.0007
ET203401	382.0487	16.6		+ O		hydroxylated (at C-5) imidazole ring	imidazole ring		365.0225
(S)						/3/, most likely structure			337.0271
PRZ_M326 * (H)	$C_{11}H_{10}Cl_3NO_4$	14.5	+	- C ₄ H ₂ N ₂ O	-	d for at least two	loss of imidazole ring and CO,	20	130.0501
ET204201	325.9748	14.5		+ OH		hydroxylations at the aliphatic part of the molecule /3/, several positional isomers	hydroxylations and further oxidations to ketones		265.9540
(S)				+ O					325.9751
				+ O					
PRZ_M298 *	$C_{11}H_{14}Cl_3NO_2$	13.3	+	- C ₄ H ₂ N ₂ O	1.4-2.9	/3/, 6 positional isomers	loss of imidazole ring and CO,	50	70.0651
ET202801	298.0163	13.3		+ O			hydroxylation		280.0061
(S)									222.9483
PRZ_M392a	$C_{15}H_{16}Cl_3N_3O_3$	14.2	+	+ O	2.1-2.5	d for hydroxylation at propyl	aliphatic hydroxylation	30	251.9742
ET202101	392.0330	14.2				side chain			69.0447
(S)						/3/, 3 positional isomers			128.0706

•	Formula [M]	RT [min] iii)	Polarity	Elemental change ^{iv)}	Log Dow v)	Identification confidence vi)	Description	CE [eV]	MS/MS confirmatory ions viii)
	Exact mass of [M+H] ⁺ /[M-H] ⁻					/level according to Schymanski et al. (2014) ¹¹ / vii)			
PRZ_M589 (H)	C ₂₄ H ₂₅ O ₈ N ₃ Cl ₃	14.8	+			/4/	unclear, most likely related to	20	282.0218
ET204001	589.0780	14.7					PRZ_M435*		308.0646
(N)									264.0748
PRZ_M374 (H)	$C_{15}H_{14}Cl_3N_3O_2$	17.0	+	- H ₂	3.5-3.7	/3/, 3 positional isomers	dehydrogenation	20	305.9851
ET205001	374.0224	17.0							277.9902
(S)									222.9478
PRZ_M397 *(H‡)	$C_{15}H_{19}Cl_3N_2O_4$	17.5	+	+ O	1.9	d, p	N loss of dihydroxylated imidazole	20	308.0010
ET204301	397.0483	17.6		+ O			ring		397.0488
(S)				- NH ₄					265.9539
PRZ_M615 * (H)	$C_{22}H_{29}Cl_3N_4O_8S$	16.5	+	- C ₃ H ₂ N ₂	-4	d, p	loss of imidazole ring,	15	486.0418
ET203701	615.0844	16.4		$+ C_{10}H_{15}N_3O_6S$		/3/, most likely structure	glutathione conjugation		383.0152
(S)									615.0841
PRZ_M386 *(H‡)	$C_{12}H_{13}Cl_3N_2O_4S$	14.2	+	- C ₃ H ₂ N ₂	0.3	D	loss of imidazole ring,	15	122.0270
ET201902	386.9734	14.2		- C ₃ H ₆		/2b/	loss of propyl side chain,		239.9739
(S)				+ C ₃ H ₅ NO ₂ S			cysteine product		386.9738
PRZ_M573.1 * (H)	$C_{24}H_{25}Cl_3N_3O_7$	16.1	+	- C ₃ HN	-1.9	d, p	partial loss of imidazole ring,	20	325.0276
ET204801	573.0830	16.2		$+ C_6 H_{10} O_5$		/3/, most likely structure	glucose conjugation,		308.0010
(N)				$+ C_3H_2O_3$			malonyl conjugation		367.0383
PRZ_M632c (H)	$C_{21}H_{26}Cl_3N_3O_{11}S$	12.7	- ^(ix)	+ O		/4/	unclear, sulfate and glucose attached	40	194.9176
ET203152	632.0281	12.7		$+ C_6 H_{10} O_8 S$			at different sites		96.9601
(S)									436.1038
PRZ_M573 *	$C_{19}H_{23}Cl_3N_4O_8S$	14.0	+	- C ₃ H ₂ N ₂	-1.9	/3/, most likely structure	loss of imidazole ring,	10	573.0375
ET203502	573.0375	14.0		- C ₃ H ₆			loss of propyl side chain,		443.9947
(S)				$+ C_{10}H_{15}N_3O_6S$			glutathione conjugation		340.9676

Compound MassBank ID of displayed MS/MS spectrum	Formula [M]	Formula [M]	RT [min] iii)	Polarity	Elemental change ^{iv)}	Log Dow v)	Identification confidence vi)	Description	CE [eV]	MS/MS confirmatory ions viii)
	Exact mass of [M+H] ⁺ / [M-H] ⁻			Change		/level according to Schymanski et al. (2014) ¹¹ / vii)		[ev]	IOIIS	
PRZ_M310 *	$C_{12}H_{14}O_2NCl_3$	16.9/17.5	+	- C ₃ H ₂ N ₂	3.7	/3/, most likely structure	loss of imidazole ring	20	136.0757	
ET205202	310.0163	16.9/17.5							149.0234	
(S)									114.0913	
PRZ_M632a	$C_{21}H_{26}Cl_3N_3O_{11}S$	10.8	- (ix)	+ O	-1.3	D for conjugation at the	aromatic hydroxylation,	40	209.9047	
ET202952	632.0281	10.7		$+ C_6 H_{10} O_5$		chlorophenyl moiety	glucose conjugation,		96.9601	
(S)				+ SO ₃		/2b/	sulfate conjugation		241.0024	
PRZ_M554a (H‡)	$C_{21}H_{26}Cl_3N_3O_8$	13.6	+	+ O	0.7-1.3	d for hydroxylation at propyl	hydroxylation at propyl side chain,	40	251.9749	
ET203801	554.0858	13.6		$+ C_6 H_{10} O_5$	$_{10}O_{5}$	side chain /3/ 3 positional isomers	glucose conjugation		69.0499	
(S)									323.9959	
PRZ_M469	$C_{15}H_{16}Cl_3N_3O_6S$	11.2	- ^(ix)	+ O	0.5	D for sulfate conjugation at	aromatic hydroxylation,	15	209.9043	
ET202051	469.9753	11.2		+ SO ₃		the chlorophenyl moiety	sulfate conjugation		96.9604	
(S)						/2b/			390.0185	
PRZ_M477	$C_{18}H_{22}Cl_2N_4O_5S$	11.2	+	$+ C_3H_6NO_2S$		d for no conjugation at the CO-imidazole ring moiety /3/, structural possibilities unclear	cysteine product,	10	381.0441	
ET203601	477.0761	11.1		+ O			hydroxylation,		409.0380	
(S)				- Cl			dehalogenation		477.0784	
PRZ_M632b	$C_{21}H_{26}Cl_{3}N_{3}O_{11}S \\$	11.4	- ^(viii)	+ O	-1.3	D for conjugation at the	aromatic hydroxylation,	40	209.9049	
ET203051	632.0281	11.3		$+ C_6H_{10}O_5$		chlorophenyl moiety /2b/	glucose conjugation,		241.0024	
(S)				+ SO ₃			sulfate conjugation		96.9602	
PRZ_M554b (H‡)	$C_{21}H_{26}Cl_3N_3O_8$	14.1	+	+ O	0.7-1.3	/3/3 positional isomers	most likely hydroxylation at propyl	40	69.0450	
ЕТ203901	554.0858	14.1		$+ C_6 H_{10} O_5$			side chain similar to PRZ_M554a,		84.0810	
(S)							glucose conjugation		280.0053	

Compound MassBank ID of displayed MS/MS spectrum	Formula [M] Exact mass of [M+H] ⁺ / [M-H] ⁻	RT [min] iii)	Polarity	Elemental change ^{iv)}	Log D _{ow} v)	Identification confidence vi) /level according to Schymanski et al. (2014) ¹¹ / vii)	Description	CE [eV]	MS/MS confirmatory ions viii)
PRZ_M515 (H‡)	515.0418	15.1	+	- C ₃ H ₂ N ₂		/3/	loss of imidazole ring,	20	282.0218
ET204402		15.1		$+ C_3H_6NO_2S$			cysteine product		86.0967
(N)				+ C ₄ H ₅ NO ₃			aspartic acid conjugation		

i) See Equation 4 in the corresponding publication for the calculation of BAFs at steady state.

 $^{^{}ii)}$ See Equation 5 in the corresponding publication for the calculation of kinetic BAF $_k$ s.

iii) In case of a retention time range, several possibly positional isomers were integrated as one peak, due to bad peak separation.

iv) The elemental change refers to the change in the molecular formula of the biotransformation product in comparison with the parent compound.

 $^{^{}y)}$ Log D_{ow} values were predicted by MarvinSketch version 14.10.20.0 at pH 7.9 and 25 °C. Log D_{ow} values correspond to corrected log K_{ow} values to account for pH-dependent dissociation. At pH 7.9 azoxystrobin is neutral thus log D_{ow} is equal to log K_{ow} . If different positional isomers are possible for one BTP, a range of log D_{ow} values is given.

vi) D: diagnostic fragment/evidence for one structure; d: diagnostic fragment/evidence for positional isomers; l: structure reported in literature; m: MS/MS data from literature; p: biotransformation pathway information; d, p: diagnostic fragment for positional isomers (d) in combination with pathway information (p) give evidence for one possible structure.

vii) Levels are defined as follows: 5 (exact mass), 4 (unequivocal molecular formula), 3 (tentative candidates: e.g., positional isomers), 2 (probable structure: library spectrum match (a) or diagnostic evidence for one structure (b)) and 1 (confirmed structure).

viii) Diagnostic fragments (d, D) are listed first and are represented in bold in the table, other characteristic fragments are then presented according to their relative abundance. Only fragments where a chemical formula and structure could be attributed are considered.

is) The sulfate-containing BTPs are more sensitive in negative ionization mode. However, they were quantified in positive ionization mode because azoxystrobin was detected and quantified in positive ionization mode.






Figure S7: Details of the proposed biotransformation pathway of prochloraz in *H. azteca* and *G. pulex* with focus on the newly identified conjugation products in *H. azteca* compared to *G. pulex*. Shown are the biotransformation reactions leading to glucose-malonyl conjugation products as well as to glutathione conjugation products and their enzymatic degradation products. BTPs written in black were detected in both species, whereas BTPs written in green are specific for *G. pulex* and BTPs written in blue are specific for *H. azteca*. Structural modifications of the BTPs are highlighted in red.

The different MassBank IDs for one compound refer to different collision energies applied during MS/MS fragmentation. The MassBank ID displayed in bold indicates the depicted MS/MS spectrum. Spectra are also available electronically in the MassBank database⁸.


Prochloraz (PRZ) MassBank ID: ET200001







PRZ_M353 *

MassBank ID: ET202601






PRZ_M325 *




PRZ_M558 * MassBank ID: ET204901




PRZ_M282 * MassBank ID: ET203201






PRZ_M323b *
MassBank ID: ET202301





PRZ_M239 * MassBank ID: ET202501




PRZ_M392b *

MassBank ID: ET202201







PRZ_M435 *




PRZ_M640 MassBank ID: ET204101




PRZ_M323a *
MassBank ID: ET202401






PRZ_M382 *




PRZ_M326 *

MassBank ID: ET204201




PRZ_M298 *

MassBank ID: ET202801




PRZ_M392a MassBank ID: ET202101



PRZ_M589


MassBank ID: ET204001

unclear structure




PRZ_M374


MassBank ID: ET205001, ET205002, ET205003, ET205004




PRZ_M397 * MassBank ID: ET204301




PRZ_M615 * MassBank ID: ET203701



PRZ_M386 * MassBank ID: ET201902




PRZ_M573.1 *
MassBank ID: ET204801




PRZ_M632c


MassBank ID: **ET203152** unclear structure




PRZ_M573 * MassBank ID: ET203502




PRZ_M310 * MassBank ID: ET205202







PRZ_M632a




PRZ_M554a MassBank ID: ET203801




PRZ_M469 MassBank ID: ET202051




PRZ_M477 MassBank ID: ET203601






PRZ_M632b




PRZ_M554b MassBank ID: ET203901



PRZ_M515 MassBank ID: ET204402

unclear structure



References

- (1) Borgmann, U. Systematic analysis of aqueous ion requirements of Hyalella azteca: A standard artificial medium including the essential bromide ion. *Arch. Environ. Contam. Toxicol.* **1996**, *30* (3), 356–363.
- (2) Rösch, A.; Anliker, S.; Hollender, J. How Biotransformation Influences Toxicokinetics of Azole Fungicides in the Aquatic Invertebrate Gammarus pulex. *Environ. Sci. Technol.* **2016**, *50* (13), 7175–7188.
- (3) Naylor, C.; Malby, L.; Callow, P. Scope for growth in Gammarus pulex, a freshwater detritivore. *Hydrobiologia* **1989**, *188*, 517–523.
- (4) Rösch, A.; Gottardi, M.; Vignet, C.; Cedergreen, N.; Hollender, J. Mechanistic understanding of the synergistic potential of azole fungicides in the aquatic invertebrate Gammarus pulex. *Environ. Sci. Technol.* **2017**, *51* (21), 12784–12795.
- (5) Ashauer, R.; Caravatti, I.; Hintermeister, A.; Escher, B. I. Bioaccumulation kinetics of organic xenobiotic pollutants in the freshwater invertebrate Gammarus pulex modeled with prediction intervals. *Environ. Toxicol. Chem.* **2010**, *29* (7), 1625–1636.
- (6) Lotufo, G. R.; Landrum, P. F.; Gedeon, M. L.; Tigue, E. A.; Herche, L. R. Comparative toxicity and toxicokinetics of DDT and its major metabolites in freshwater amphipods. *Environ. Toxicol. Chem.* **2000**, *19* (2), 368–379.
- (7) Jager, T.; Øverjordet, I. B.; Nepstad, R.; Hansen, B. H. Dynamic Links between Lipid Storage, Toxicokinetics and Mortality in a Marine Copepod Exposed to Dimethylnaphthalene. *Environ. Sci. Technol.* **2017**, *51* (13), 7707–7713.
- (8) R Core Team. A language and environment for statistical computing, R Foundation for Statistical Computing. 2016.
- (9) Ritz, C.; Streibig, J. C.; Ritz, C. & Streibig, J. C. Bioassay Analysis using R. *J. Stat. Softw.* **2005**, *12* (5), 1–22.
- (10) European Mass Bank Server (NORMAN MassBank) www.massbank.eu.
- (11) Schymanski, E. L.; Jeon, J.; Gulde, R.; Fenner, K.; Ruff, M.; Singer, H. P.; Hollender, J. Identifying small molecules via high resolution mass spectrometry: communicating confidence. *Environ. Sci. Technol.* **2014**, *48*, 2097–2098.
- (12) Debrauwer, L.; Rathahao, E.; Boudry, G.; Baradat, M.; Cravedi, J. P. Identification of the major metabolites of prochloraz in rainbow trout by liquid chromatography and tandem mass spectrometry. *J. Agric. Food Chem.* **2001**, *49* (8), 3821–3826.
- (13) Needham, D.; Challis, I. R. The metabolism and excretion of prochloraz, an imidazole-based fungicide, in the rat. *Xenobiotica* **1991**, *21* (11), 1473–1482.
- (14) Roberts, T. R.; Hutson, D. H.; Lee, P. W.; Nicholls, P. H.; Plimmer, J. R. *Metabolic Pathways of Agrochemicals: Part 2: Insecticides and Fungicides*; Royal Society of Chemistry, 2007.
- (15) Laignelet, L.; Rivière, J. L.; Lhuguenot, J. C. Metabolism of an imidazole fungicide (prochloraz) in the rat after oral administration. *Food Chem. Toxicol.* **1992**, *30* (7), 575–583.